Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, multicenter study comparing the immediate adjuvant radiotherapy associate with hormonal therapy of LH-RH analogue (Decapeptyl LP) vs delayed radiotherapy until biochemical relapse associated with hormonal therapy of LH-RH analogue (Decapeptyl LP) in patients with operable prostate cancer pT3 R1 pN0 or pNx at intermediate risk.

X
Trial Profile

Randomized, multicenter study comparing the immediate adjuvant radiotherapy associate with hormonal therapy of LH-RH analogue (Decapeptyl LP) vs delayed radiotherapy until biochemical relapse associated with hormonal therapy of LH-RH analogue (Decapeptyl LP) in patients with operable prostate cancer pT3 R1 pN0 or pNx at intermediate risk.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2020 Primary endpoint has not been met. (Event-free survival (clinical progression, biochemical progression, death) at 5 years)
    • 01 Oct 2020 Status changed from active, no longer recruiting to discontinued.
    • 01 Oct 2020 Results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top